Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

81. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, Meyer-Sabellek W, Buhl (...) R, Willich S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two strategies for the treatment of asthma were examined, adjustable maintenance versus fixed treatment. Both strategies were based on a combination of budesonide

NHS Economic Evaluation Database.2005

82. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Lofdahl C G, Ericsson A, Svensson K, Andreasson E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the combination of budesonide and formoterol (B/F) in a single inhaler for the treatment of chronic obstructive pulmonary disease (COPD). The patients received two inhalations of B/F (160/4.5 microg) twice daily. Type of intervention Treatment. Economic study type

NHS Economic Evaluation Database.2005

83. Budesonide once versus twice-daily administration: meta-analysis

Budesonide once versus twice-daily administration: meta-analysis Budesonide once versus twice-daily administration: meta-analysis Budesonide once versus twice-daily administration: meta-analysis Masoli M, Weatherall M, Holt S, Beasley R CRD summary This review compared budesonide given once versus twice daily for the treatment of asthma. The authors concluded that once-daily administration had similar efficacy to twice-daily administration for the treatment of mild to moderate asthma. However (...) , the lack of a validity assessment threatens the reliability of the authors' conclusion. Authors' objectives To determine the efficacy of budesonide administered once daily compared with twice daily for the treatment of asthma. Searching MEDLINE (from 1966 to 2003) and EMBASE (from 1980 to 2003) were searched using the terms reported. There was no language restrictions. The reference lists of relevant articles were examined and the manufacturer was contacted for additional studies. Study selection Study

DARE.2004

84. Country-specific cost-effectiveness early intervention with budesonide in mild asthma

Country-specific cost-effectiveness early intervention with budesonide in mild asthma Country-specific cost-effectiveness early intervention with budesonide in mild asthma Country-specific cost-effectiveness early intervention with budesonide in mild asthma Buxton M J, Sullivan S D, Andersson L F, Lamm C, Liljas B, Busse W W, Pedersen S, Weiss K B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined early intervention with low-dose budesonide (Pulmicort, Turbuhaler) in adult patients with mild persistent asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with mild persistent asthma. The patients were aged between 5

NHS Economic Evaluation Database.2004

85. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study

An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study Price D, Haughney J, Lloyd A, Hutchinson J, Plumb J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the Symbicort Turbohaler, a budesonide/formoterol combination, for the treatment of patients with asthma in primary care. The drug combination was administered as either an adjustable maintenance

NHS Economic Evaluation Database.2004

86. Budesonide/eformoterol (Symbicort)

Budesonide/eformoterol (Symbicort) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Budesonide/formoterol inhaler (Symbicort Turbohaler Ò ) No. 97/04 AstraZeneca UK Ltd Summary of Recommendation 10 May, 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS (...) Scotland. The recommendation is summarised as follows: Advice: following a full submission. Budesonide/formoterol inhaler (Symbicort Turbohaler ® ) is accepted for use within NHS Scotland for the symptomatic treatment of patients with severe COPD (FEV 1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. It is the second of two long-acting ß 2 -agonist/corticosteroid combination inhaler preparations

Scottish Medicines Consortium2004

87. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma

Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma Sullivan S D, Buxton M, Andersson L F, Lamm C J, Liljas B, Chen Y Z, Pauwels R A, Weiss K B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of budesonide (Pulmicort Turbohaler; AstraZeneca), once daily, for the treatment of mild persistent asthma. The dose was 200 microg for children aged younger than 11 years and 400 microg for other patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

NHS Economic Evaluation Database.2003

88. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial.

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. 12672309 2003 04 03 2003 04 24 2017 02 07 0140-6736 361 9363 2003 Mar 29 Lancet (London, England) Lancet Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. 1071-6 Although inhaled glucocorticosteroids are recommended for persistent asthma, their long-term effect on recent onset, mild, persistent asthma has yet to be established. We did a randomised, double (...) -blind clinical trial in 7241 patients in 32 countries to assess the effects of budesonide in patients who had had mild persistent asthma for less than 2 years and who had not had previous regular treatment with glucocorticosteroids. Patients aged 5-66 years received either budesonide or placebo once daily for 3 years in addition to their usual asthma medications. The daily budesonide dose was 400 microg, or 200 microg for children younger than 11 years. The primary outcome was time to first severe

Lancet2003

89. Systematic review: the effectiveness of budesonide therapy for Crohn's disease

Systematic review: the effectiveness of budesonide therapy for Crohn's disease Systematic review: the effectiveness of budesonide therapy for Crohn's disease Systematic review: the effectiveness of budesonide therapy for Crohn's disease Kane S V, Schoenfeld P, Sandborn W J, Tremaine W, Hofer T, Feagan B G Authors' objectives To assess the effectiveness and safety of budesonide in comparison with corticosteroids, 5-aminosalicylic acid (5-ASA) or placebo, for inducing remission of active Crohn's (...) disease and for maintaining remission. Searching MEDLINE and EMBASE were searched from 1980 to 2001 for articles in any language. The search terms used were 'budesonide', 'Crohn disease', 'therapy', 'clinical trial' and 'randomized (pt)'. In addition, reference lists and conference proceedings of the American Gastroenterological Association and the American College of Gastroenterology were handsearched. Researchers and drug companies were contacted for unpublished trials. Study selection Study designs

DARE.2002

90. Fluticasone versus beclomethasone or budesonide for chronic asthma.

Fluticasone versus beclomethasone or budesonide for chronic asthma. BACKGROUND: Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays. OBJECTIVES: To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma. SEARCH STRATEGY: We searched the Cochrane Airways Group Trial Register (...) (1999) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999). SELECTION CRITERIA: Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality. DATA COLLECTION AND ANALYSIS: One reviewer extracted data

Cochrane2002

91. Inhaled beclomethasone versus budesonide for chronic asthma.

Inhaled beclomethasone versus budesonide for chronic asthma. BACKGROUND: Beclomethasone dipropionate (BDP) and budesonide (BUD) are used widely in the treatment of chronic asthma. The two drugs have different in vitro pharmacokinetic characteristics. It is unclear whether this translates into clinically significant differences in efficacy or safety when treating children and adults with chronic asthma. OBJECTIVES: To assess clinical outcomes in studies which have compared inhaled BDP and BUD

Cochrane2002

92. Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study

Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Andersson F, Stahl E, Barnes P J, Lofdahl C G, O'Byrne P M, Pauwels R A, Postma D S, Tattersfield A E, Ullman A Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four treatments for patients with persistent symptoms of asthma were examined: low-dose budesonide (total daily dose 200 microg) plus placebo; low-dose budesonide plus formoterol (total daily dose 24 microg); moderate-dose budesonide (total daily dose 800 microg) plus placebo

NHS Economic Evaluation Database.2001

93. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice

Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Andersson F, Kjellman M, Forsberg G, Moller C, Arheden L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two maintenance therapies for the management of childhood asthma were compared: budesonide and sodium cromoglycate, both recommended strategies in Sweden. Type of intervention Treatment. Economic study type

NHS Economic Evaluation Database.2001

94. Budesonide for maintenance of remission in Crohn's disease.

Budesonide for maintenance of remission in Crohn's disease. OBJECTIVES: The primary objective was to precisely derive an estimate of the efficacy of oral budesonide for the maintenance of remission in Crohn's disease. SEARCH STRATEGY: Medline 1966-September 2000 was searched using the text and key words "oral budesonide", "Crohn's disease", "Crohn disease", and "inflammatory bowel disease". Proceedings from the American Gastroenterology Association conference (1980-1998) were hand searched (...) . Additionally, the Cochrane Controlled Trials Register and the Inflammatory Bowel Disease Review Group Trials Registers were also searched. The manufacturer of oral budesonide was also contacted, as were some of the local trialists involved in the oral budesonide trials. Relevant articles were retrieved, and their reference lists were also reviewed. SELECTION CRITERIA: Randomized controlled trials of oral budesonide in which patients at entry were in remission with a Crohn's Disease Activity Index (CDAI

Cochrane2001

95. Budesonide at different doses for chronic asthma.

Budesonide at different doses for chronic asthma. BACKGROUND: Inhaled budesonide (BUD) is available in a range of doses for treating chronic asthma. OBJECTIVES: To quantitatively assess the efficacy and safety of budesonide at different doses in order to establish whether a clinically significant dose response profile exists. SEARCH STRATEGY: A search was carried out for Controlled and Randomised Clinical Trials (RCTs) using the Cochrane Airways Group trial register, correspondence with trial (...) authors and the manufacturer. SELECTION CRITERIA: Randomised trials in children and adults comparing one dose of budesonide to a second dose in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality. DATA COLLECTION AND ANALYSIS: One reviewer extracted data; authors were contacted to clarify missing information. Quantitative analyses where undertaken using Review Manager. MAIN RESULTS: 24 studies were selected for inclusion in the review

Cochrane2001

96. Budesonide for chronic asthma in children and adults.

Budesonide for chronic asthma in children and adults. BACKGROUND: Inhaled budesonide is a widely used inhaled corticosteroid for asthma. OBJECTIVES: The objectives of this review was to compare the efficacy of budesonide with placebo in the treatment of chronic asthma. SEARCH STRATEGY: The Cochrane Airways Group Trial Register and reference lists of articles was searched. We contacted trialists for additional studies and searched abstracts of major respiratory society meetings (1997-1999 (...) ). SELECTION CRITERIA: Randomised trials in children and adults comparing budesonide to placebo in the treatment of chronic asthma. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed articles for inclusion and methodological quality. One reviewer extracted data. MAIN RESULTS: 43 studies met the inclusion criteria (2801 subjects). In non-oral steroid treated asthmatics, budesonide led to significant improvements in a number of measures of airway function. These included FEV1, Weighted Mean

Cochrane2001

97. Budesonide in the treatment of Crohn's disease: a meta-analysis

Budesonide in the treatment of Crohn's disease: a meta-analysis Budesonide in the treatment of Crohn's disease: a meta-analysis Budesonide in the treatment of Crohn's disease: a meta-analysis Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L Authors' objectives To perform a meta-analysis to assess the effectiveness and safety of oral budesonide for inducing remission in active Crohn's disease and for preventing relapse in Crohn's disease with medically- or surgically-induced remission (...) . Searching MEDLINE (from initiation to date of search) was searched using the following MeSH terms: 'budesonide' and 'Crohn' or 'inflammatory bowel disease'. A manual search of review articles and proceedings from major gastrointestinal meetings (1993-1999) was also performed, and the bibliographies of retrieved articles searched. Only results fully reported in journal articles were included. No language restrictions were reported. Study selection Study designs of evaluations included in the review

DARE.2000

98. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily (...) and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback B, Jenkins C, Price M J, Thwaites R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Salmeterol/fluticasone propionate combination

NHS Economic Evaluation Database.2000

99. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis

Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Stahl E, van Rompay W, Wang E C, Thomson D M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Budesonide aqueous nasal spray and fluticasone propionate allergic spray in the treatment of perennial allergic rhinitis (PAR). Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2000

100. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis

A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis Keith P K, Haddon J, Birch S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intranasal budesonide for seasonal allergic rhinitis. Type of intervention Treatment. Economic study type Cost-benefit analysis. Study population Patients suffering from seasonal allergic rhinitis. Setting Community. The study was carried out in Canada. Dates to which data relate

NHS Economic Evaluation Database.2000